249 related articles for article (PubMed ID: 29663615)
1. Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
[No Abstract] [Full Text] [Related]
2. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
Dogra S; Bishnoi A; Narang T; Handa S
Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
[No Abstract] [Full Text] [Related]
3. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
Lo Y; Tsai TF
Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
[No Abstract] [Full Text] [Related]
5. Erythrodermic psoriasis peculiarly sparing anti-TNF injection sites in a patient with secondary loss of efficacy.
Kapoor DM; Tan KW
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28976682
[No Abstract] [Full Text] [Related]
6. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
7. Erythrodermic psoriasis.
Mumoli N; Vitale J; Gambaccini L; Sabatini S; Brondi B; Cei M
QJM; 2014 Apr; 107(4):315. PubMed ID: 23764512
[No Abstract] [Full Text] [Related]
8. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
9. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Lisby S; Gniadecki R
Acta Derm Venereol; 2004; 84(3):247-8. PubMed ID: 15202853
[No Abstract] [Full Text] [Related]
10. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
11. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
12. Erythrodermic psoriasis with bullous pemphigoid: combination treatment with methotrexate and compound glycyrrhizin.
Si X; Ge L; Xin H; Cao W; Sun X; Li W
Diagn Pathol; 2014 May; 9():102. PubMed ID: 24885087
[TBL] [Abstract][Full Text] [Related]
13. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab.
Rongioletti F; Borenstein M; Kirsner R; Kerdel F
J Dermatolog Treat; 2003 Dec; 14(4):222-5. PubMed ID: 14660268
[TBL] [Abstract][Full Text] [Related]
14. Excessive hair growth in a patient with psoriatic erythroderma following secukinumab administration.
Mashima E; Sawada Y; Yamaguchi T; Yoshioka H; Ohmori S; Haruyama S; Okada E; Nakamura M
Eur J Dermatol; 2018 Aug; 28(4):539-540. PubMed ID: 30325327
[No Abstract] [Full Text] [Related]
15. Erythrodermic psoriasis improved by panitumumab, but not bevacizumab.
Nishizawa A; Satoh T; Yokozeki H
Acta Derm Venereol; 2012 Jul; 92(4):360-1. PubMed ID: 22565356
[No Abstract] [Full Text] [Related]
16. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
17. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis.
Mugheddu C; Atzori L; Lappi A; Pau M; Murgia S; Rongioletti F
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e420-e421. PubMed ID: 28319281
[No Abstract] [Full Text] [Related]
18. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
[TBL] [Abstract][Full Text] [Related]
19. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
Peccerillo F; Odorici G; Pellacani G; Conti A
Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
[No Abstract] [Full Text] [Related]
20. Psoriatic Erythroderma Caused by Terbinafine: A Possible Pathogenetic Role for IL-23.
Oda T; Sawada Y; Yamaguchi T; Ohmori S; Omoto D; Haruyama S; Yoshioka M; Okada E; Nakamura M
J Investig Allergol Clin Immunol; 2017; 27(1):63-64. PubMed ID: 28211348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
